树突状细胞与丙型病毒性肝炎

魏峰; 李俊卿; 周俊英

树突状细胞与丙型病毒性肝炎

河北医科大学第三医院感染科

详细信息

中图分类号: R392
计量
- 文章访问数: 3238
- HTML全文浏览量: 17
- PDF下载量: 806
- 被引次数: 0
出版历程
- 出版日期: 2011-05-20

Dendritic cells and hepatitis C

摘要

摘要: 树突状细胞(DC)是目前已知体内功能最强的抗原递呈细胞,在丙型肝炎病毒(HCV)感染的患者,DC功能减弱可促进病毒的持续感染,造成疾病的慢性化。目前DC成为HCV疫苗的研究重点,可能成为治疗慢性丙型肝炎(CHC)的有效免疫学方法,本文就DC与丙型肝炎的关系及其在治疗中的应用前景作一综述。
- 肝炎,丙型 /
- 树突状细胞
Abstract: Dendritic cells (DCs) are currently known as the most powerful antigen-presenting cells.In patients with HCV infection, dysfunction of DCs can cause persistent viral infection leading to chronicity of the disease.DCs have become an important research focus for HCV vaccination, and it will be an effective immunology method for the treatment of viral hepatitis C.In this review, we summarized the relationship of DCs in viral hepatitis C and its perspective in the role of treatment.
- hepatitis C /
- dendritic cells

HTML全文

参考文献(21)

[1]Pachiadakis I, Pollara G, Chain BM, et al.Is hepatitis C virus infection of dendritic cells a mechanism facilitating viral persistence[J].Lancet Infect Dis, 2005, 5 (5) :296-304.

[2]Groux H, Foumier N, Cottrez F.Role of dendritic cells in the generation of regulatory T cells[J].Semin Immunol, 2004, 6 (2) :99-106.

[3]Onishi Y, Fehervari Z, Yamaguchi T, et al.Foxp3+natural resulatery T cells pmferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation[J].Proc Natl Acad Sci, 2008, 105 (29) :10113-10118.

[4]Kanto T, Hayashi N, Takehara T, et al.Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals[J].J Immunol, 1999, 162 (9) :5584-5591.

[5]Li W, Krishnadas DK, Kumar R, et al.Priming and stimulation of hepatitis C virus-specific CD4+and CD8+T cells against HCV antigens NS4, NS5a or NS5b from HCV-naive individuals:implications for prophylactic vaccine[J].Int Immunol, 2008, 20 (1) :89-104.

[6]Amjad M, Abdel-Haq N, Faisal M, et al.Decreased interferon-alpha production and impaired regulatory function of plasmacytoid dendritic cells induced by the hepatitis C virus NS 5 protein[J].Microbiol Immunol, 2008, 52 (10) :499-507.

[7]Bain C, Fatmi A, Zoulim F, et al.Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection[J].Gastroenterology, 2001, 120 (33) :512-524.

[8]李军, 冯志华, 聂青和, 等.人DC-SIGN真核表达载体的构建及在K-562细胞中的表达[J].肝脏, 2006, 11 (1) :24-27.

[9]王敏, 王辉, 蒋小玲, 等.DC-SIGNR基因多态性与肝功能和HCV病毒载量的相关性[J].中国医师进修杂志, 2007, 30 (30) :3-5.

[10]Auffermann-Gretzinger S, Keeffe EB, Levy S.Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection[J].Blood, 2001, 97 (18) :3171-3176.

[11]Dolganiuc A, Kodys K, Kopasz A, et al.Hepatitis C virus core and nonstructural protein 3 proteins induce pro-and anti-inflammatory cytokines and inhibit tendritic cell differentiation[J].J Immunol, 2003, 170 (11) :5615-5624.

[12]Zimmermann M, Flechsig C, La Monica N, et al.Hepatitis C virus core protein impairs in vitro priming of specific T cell responses by dendritic cells and hepatocytes[J].J Hepatol, 2008, 48 (1) :51-60.

[13]Dolganiuc A, Paek E, Kodys K, et al.Myeloid den-dritic cells of patients with chronic HCV infection induce proliferation of regulatory T lymphocytes[J].Gastroenterology.2008, 135 (6) :2119-2127.

[14]Lai WK, Curbishley SM, Goddard S, et al.Hepatitis C is associated with perturbation of intrahepatic myeloid and plasmacytoid dendritic cell function[J].J Hepatol, 2007, 47 (3) :338-347.

[15]Klade CS, Wedemeyer H, Berg T, et al.Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41[J].Gastroenterology, 2008, 134 (5) :1385-1395.

[16]Firbas C, Boehm T, Buerger V, et al.Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine[J].Vaccine, 2010, 28 (12) :2397-2407.

[17]Chua BY, Eriksson EM, Brown LE, et al.A self-adj-uvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection[J].Vaccine, 2008, 26 (37) :4866-4875.

[18]Gowans EJ, Roberts S, Jones K, et al.A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals[J].J Hepatol, 2010, 53 (4) :599-607.

[19]Zabaleta A, Llopiz D, Arribillaga L, et al.Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein[J].Mol Ther, 2008, 16 (1) :210-217.

[20]Yu H, Babiuk LA, van Drunen Littel-van den Hurk S.Strategies for loading dendritic cells with hepatitis C NS5a antigen and inducing protective immunity[J].J Viral Hepat, 2008, 15 (6) :459-470.

[21]Forde KA, Reddy KR.Hepatitis C virus infection and immunomodulatory therapies[J].Clin Liver Dis, 2009, 13 (3) :391-401.

施引文献

资源附件(0)

访问统计